Prominent publications by Matthew G Law

KOL Index score: 18565

BACKGROUND: The national quadrivalent human papillomavirus (4vHPV) vaccination programme was launched in Australia in April, 2007. In this study, we aimed to explore the prevalence of vaccine-targeted human papillomavirus (HPV) types contained in the 4vHPV and nine-valent HPV (9vHPV) vaccines detected in young women diagnosed with chlamydia.

METHODS: In this cross-sectional study, we identified specimens from women aged 25 years or younger who attended the Melbourne Sexual Health Centre ...

Also Ranks for: Young Women |  papillomavirus vaccination |  vaccines prevalence |  chlamydia trachomatis |  hpv types
KOL Index score: 18549

OBJECTIVE: Metabolic syndrome is a cluster of risk factors for cardiovascular disease and type 2 diabetes. Definitions exist to identify those "at risk." Treatment of HIV infection with highly active antiretroviral therapy can induce severe metabolic complications including lipodystrophy, dyslipidemia, and insulin resistance. The purpose of this study was to report the prevalence of metabolic syndrome in HIV-infected patients and compare insulin resistance and total body, limb, and ...

Also Ranks for: Metabolic Syndrome |  insulin resistance |  active antiretroviral |  infected patients |  body fat
KOL Index score: 17281

OBJECTIVE: To describe a syndrome of peripheral lipodystrophy (fat wasting of the face, limbs and upper trunk), hyperlipidaemia and insulin resistance in patients receiving potent HIV protease inhibitor therapy.

DESIGN: Cross-sectional study.

SETTING: Outpatient clinic of a university teaching hospital.

PATIENTS: HIV-infected patients either receiving at least one protease inhibitor (n=116) or protease inhibitor-naive (n=32), and healthy men (n=47).


Also Ranks for: Peripheral Lipodystrophy |  insulin resistance |  hiv protease |  triglyceride levels |  body composition
KOL Index score: 16429

BACKGROUND & AIMS: This study evaluates trends in hepatocellular carcinoma (HCC) among people with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection in New South Wales (NSW), Australia between 2000 and 2014.

METHODS: Data on HBV and HCV notifications between January 1993 and December 2012 were linked to the NSW Admitted Patients Data Collection database between July 2000 and June 2014 and NSW Registry of Births Deaths and Marriages. The burden, crude and age-standardised ...

Also Ranks for: Hepatocellular Carcinoma |  hcv hcc |  hepatitis virus |  australia hbv |  new south
KOL Index score: 16322

BACKGROUND & AIMS: HCV reinfection following successful treatment can compromise treatment outcomes. This systematic review assessed the rate of HCV reinfection following treatment among people with recent drug use and those receiving opioid agonist therapy (OAT).

METHODS: We searched bibliographic databases and conference abstracts for studies assessing post-treatment HCV reinfection rates among people with recent drug use (injecting or non-injecting) or those receiving OAT. ...

Also Ranks for: Treatment People |  reinfection rates |  95 drug |  opioid agonist therapy |  rate hcv
KOL Index score: 15624

BACKGROUND: Immediate initiation of antiretroviral therapy (ART) in asymptomatic adults with CD4 counts higher than 500 cells per μL, as recommended, might not always be possible in resource-limited settings. We aimed to identify subgroups of individuals who would benefit most from immediate treatment.

METHODS: The START trial was a randomised controlled trial in asymptomatic, HIV-positive adults previously untreated with ART. Participants with CD4 counts higher than 500 cells per μL ...

Also Ranks for: Antiretroviral Therapy |  start trial |  art cd4 |  cd8 ratio |  500 cells
KOL Index score: 15401

BACKGROUND: Frequent testing of individuals at high risk of HIV is central to current prevention strategies. We aimed to determine if HIV self-testing would increase frequency of testing in high-risk gay and bisexual men, with a particular focus on men who delayed testing or had never been tested before.

METHODS: In this randomised trial, HIV-negative high-risk gay and bisexual men who reported condomless anal intercourse or more than five male sexual partners in the past 3 months were ...

Also Ranks for: Hiv Testing |  gay bisexual |  infections homosexuality |  tests year |  facility based
KOL Index score: 15269

BACKGROUND: We assessed the effects of hepatitis B (HBV) or hepatitis C (HCV) co-infection on outcomes of antiretroviral therapy (ART) in HIV-infected patients enrolled in the TREAT Asia HIV Observational Database (TAHOD), a multi-center cohort of HIV-infected patients in the Asia-Pacific region.

METHODS: Patients testing HBs antigen (Ag) or HCV antibody (Ab) positive within enrollment into TAHOD were considered HBV or HCV co-infected. Factors associated with HBV and/or HCV co-infection ...

Also Ranks for: Hiv Patients |  hcv infection |  hepatitis hbv |  treat asia |  observational database
KOL Index score: 14687

BACKGROUND: Although earlier protease inhibitors have been associated with increased risk of cardiovascular disease, whether this increased risk also applies to more contemporary protease inhibitors is unknown. We aimed to assess whether cumulative use of ritonavir-boosted atazanavir and ritonavir-boosted darunavir were associated with increased incidence of cardiovascular disease in people living with HIV.

METHODS: The prospective Data Collection on Adverse Events of Anti-HIV Drugs ...

Also Ranks for: Cardiovascular Disease |  protease inhibitors |  1000 personyears |  darunavir ritonavir |  people hiv
KOL Index score: 14493

CONTEXT: Immune suppression after organ transplantation is associated with a markedly increased risk of nonmelanoma skin cancer and a few virus-associated cancers. Although it is generally accepted that other cancers do not occur at increased rates, there have been few long-term population-based cohort studies performed.

OBJECTIVE: To compare the incidence of cancer in patients receiving immune suppression after kidney transplantation with incidence in the same population in 2 periods ...

Also Ranks for: Kidney Transplantation |  cancer incidence |  immune suppression |  increased rates |  specific population
KOL Index score: 14216

BACKGROUND: With the advent of effective antiretroviral treatment, the life expectancy for people with HIV is now approaching that seen in the general population. Consequently, the relative importance of other traditionally non-AIDS-related morbidities has increased. We investigated trends over time in all-cause mortality and for specific causes of death in people with HIV from 1999 to 2011.

METHODS: Individuals from the Data collection on Adverse events of anti-HIV Drugs (D:A:D) study ...

Also Ranks for: Death People |  1000 personyears |  liver disease |  multicohort collaboration |  cd4 cell count
KOL Index score: 14153

BACKGROUND & AIMS: The risk of hepatocellular carcinoma (HCC) occurrence or recurrence following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. The aims of this study were to compare the rate of HCC occurrence in patients with HCV-related cirrhosis, following DAA vs. interferon (IFN)-based cure, and to compare the rate of HCC recurrence in patients who received curative HCC treatment, following DAA vs. IFN-based cure.

METHODS: A search was conducted for ...

Also Ranks for: Hcc Occurrence |  hcv therapy |  carcinoma risk |  recurrence patients |  acting antiviral
KOL Index score: 13942

OBJECTIVE: To describe the incidence of non-AIDS-defining cancers in people with HIV infection before and after the occurrence of AIDS, and to examine the association of cancer risk with immune deficiency.

DESIGN: Cohort study involving nation-wide linkage of HIV, AIDS and cancer registry data.

METHODS: Association of cancer risk with immune deficiency was examined by analysing cancer risks in four periods between HIV diagnosis, AIDS and death.

RESULTS: Linkage identified 196 cases of ...

Also Ranks for: Hiv Infection |  aids diagnosis |  defining cancers |  cancer risk |  immune deficiency
KOL Index score: 13786

OBJECTIVES: To determine if there were any differences in antiretroviral treatment (ART) use across the three eastern states of Australia, New South Wales (NSW), Victoria and Queensland, during the period 1997 to 2006.

METHODS: We used data from a clinic-based cohort, the Australian HIV Observational Database (AHOD), to determine the proportion of HIV-infected patients on ART in selected clinics in each state and the proportion of treated patients with an undetectable viral load. Data ...

Also Ranks for: Antiretroviral Treatment |  australian states |  art nsw |  victoria queensland |  infections homosexuality
KOL Index score: 13755

BACKGROUND & AIMS: Population-level evidence for the impact of direct-acting antiviral (DAA) therapy on hepatitis C virus (HCV)-related disease burden is lacking. We aimed to evaluate trends in HCV-related decompensated cirrhosis and hepatocellular carcinoma (HCC) hospitalisation, and liver-related and all-cause mortality in the pre-DAA (2001-2014) and DAA therapy (2015-2017) eras in New South Wales, Australia.

METHODS: HCV notifications (1993-2016) were linked to hospital admissions ...

Also Ranks for: New South Wales |  liver disease |  decompensated cirrhosis |  antiviral therapy |  hcc diagnosis

Key People For Antiretroviral Therapy

Top KOLs in the world
Andrew * *********
antiretroviral therapy viral load hiv infection
Jens ******* ********
antiretroviral therapy hiv infection viral load
Peter ******
antiretroviral therapy hiv infection myocardial infarction
David * ******
antiretroviral therapy hiv infection viral load
Joseph * ****
antiretroviral therapy united states hiv infection
Douglas * ********
antiretroviral therapy hiv infection human immunodeficiency virus

Matthew G Law:Expert Impact

Concepts for whichMatthew G Lawhas direct influence:Antiretroviral therapy,  Hiv infection,  Cardiovascular disease,  Myocardial infarction,  New south wales.

Matthew G Law:KOL impact

Concepts related to the work of other authors for whichfor which Matthew G Law has influence:Antiretroviral therapy,  Hiv infection,  Human immunodeficiency virus,  Hepatocellular carcinoma,  Cardiovascular disease,  Infected patients,  Chronic hepatitis.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

The Kirby Institute, UNSW Sydney, Sydney, Australia | The Kirby Institute, University of New South Wales Sydney, Sydney, NSW, Australia. | Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia | The Kirby Institute, Unive